Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 8135-8147

  Campbell, Christopher T ^a   Aich, Udayanath ^a   Weier, Christopher A ^a   Wang, Jean J ^a   Choi, Sean S ^a   Wen, Mary M ^a   Maisel, Katharina ^a   Sampathkumar, Srinivasa Gopalan ^a,c   Yarema, Kevin J ^a,b  

^a Johns Hopkins University   (United States)

^b Clark Hall 106A ^*  (United States)

^c NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,6 PENTA O BUTANOYL ALPHA,BETA DEXTRO MANNOPYRANOSE; 2 ACETAMIDO 2 DEOXY 1,3,4,6 TETRA O BUTANOYL ALPHA,BETA DEXTRO MANNOPYRANOSE; BUTYRIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CXCR4; GELATINASE B; HEXOSAMINE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUCIN 1; PER BUTANOYLATED DEXTRO MANNOSE; PER BUTANOYLATED N ACETYL DEXTRO MANNOSAMINE; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER INVASION; CELL MOTILITY; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOLECULAR MODEL; ONCOGENE; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; EPIGENESIS, GENETIC; FATTY ACIDS; HEXOSAMINES; HUMANS; MATRIX METALLOPROTEINASE 9; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NF-KAPPA B; RECEPTORS, CXCR4;

EID: 58149097138     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800873k     Document Type: Article

References (41)

1. Keppler, O. T.; Horstkorte, R.; Pawlita, M.; Schmidt, C.; Reutter, W. Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. Glycobiology 2001, 11, 11R-18R.
2. Campbell, C. T.; Sampathkumar, S.-G.; Weier, C.; Yarema, K. J. Metabolic oligosaccharide engineering: perspectives, applications, and future directions. Mol. Biosyst. 2007, 3, 187-194.
3. Sarkar, A. K.; Fritz, T. A.; Taylor, W. H.; Esko, J. D. Disaccharide uptake and priming in animal cells: inhibition of sialyl Lewis X by acetylated Gal β1,4GlcNAc β-O-naphthalenemethanol. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3323-3327.
4. Jones, M. B.; Teng, H.; Rhee, J. K.; Baskaran, G.; Lahar, N.; Yarema, K. J. Characterization of the cellular uptake and metabolic conversion of acetylated N-acetylmannosamine (ManNAc) analogues to sialic acids. Biotechnol. Bioeng. 2004, 85, 394-405.
5. Sampathkumar, S.-G.; Campbell, C. T.; Weier, C.; Yarema, K. J. Short-chain fatty acid-hexosamine cancer prodrugs: The sugar matters! Drugs Future 2006, 31, 1099-1116.
6. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
7. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12, 1247-1252.
8. Kayser, H.; Zeitler, R.; Kannicht, C.; Grunow, D.; Nuck, R.; Reutter, W. Biosynthesis of a nonphysiological sialic acid in different rat organs, using N-propanoyl-D-hexosamines as precursors. J. Biol. Chem. 1992, 267, 16934-16938.
9. Mahal, L. K.; Yarema, K. J.; Bertozzi, C. R. Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis. Science 1997, 276, 1125-1128.
10. Lemieux, G. A.; Yarema, K. J.; Jacobs, C. L.; Bertozzi, C. R. Exploiting differences in sialoside expression for selective targeting of MRI contrast reagents. J. Am. Chem. Soc. 1999, 121, 4278-4279.
11. Jacobs, C. L.; Yarema, K. J.; Mahal, L. K.; Nauman, D. A.; Charters, N.; Bertozzi, C. R. Metabolic labeling of glycoproteins with chemical tags through unnatural sialic acid biosynthesis. Methods Enzymol. 2000, 327, 260-275.
12. Kim, E. J.; Sampathkumar, S.-G.; Jones, M. B.; Rhee, J. K.; Baskaran, G.; Yarema, K. J. Characterization of the metabolic flux and apoptotic effects of O-hydroxyl- and N-acetylmannosamine (ManNAc) analogs in Jurkat (human T-lymphoma-derived) cells. J. Biol. Chem. 2004, 279, 18342-18352.
13. Pouillart, P.; Douillet, O.; Scappini, B.; Gozzini, A.; Santini, V.; Grossi, A.; Pagliai, G.; Strippoli, P.; Rigacci, L.; Ronco, G.; Villa, P. Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: influence of alkyl chain length on acute toxicity. Eur. J. Pharm. Sci. 1999, 7, 93-106.
14. Sampathkumar, S.-G.; Jones, M. B.; Meledeo, M. A.; Campbell, C. T.; Choi, S. S.; Hida, K.; Gomutputra, P.; Sheh, A.; Gilmartin, T.; Head, S. R.; Yarema, K. J. Targeting glycosylation pathways and the cell cycle: sugar-dependent activity of butyrate-carbohydrate cancer prodrugs. Chem. Biol. 2006, 13, 1265-1275.
15. Aich, U.; Campbell, C. T.; Elmouelhi, N.; Weier, C. A.; Sampathkumar, S.-G.; Choi, S. S.; Yarema, K. J. Regioisomeric SCFA attachment to hexosamines separates metabolic flux from cytotoxcity and MUC1 suppression. ACS Chem. Biol. 2008, 3, 230-240.
16. Chen, L.-F.; Greene, W. C. Shaping the nuclear action of NF-κB. Nat. Rev. Mol. Cell. Biol. 2004, 5, 392-401.
17. Lavis, L. D. Ester bonds in prodrugs. ACS Chem. Biol. 2008, 3, 203-206.
18. Kim, E. J.; Jones, M. B.; Rhee, J. K.; Sampathkumar, S.-G.; Yarema, K. J. Establishment of N-acetylmannosamine (ManNAc) analogue-resistant cell lines as improved hosts for sialic acid engineering applications. Biotechnol. Prog. 2004, 20, 1674-1682.
19. Finnie, I. A.; Dwarakanath, A. D.; Taylor, B. A.; Rhodes, J. M. Colonic mucin synthesis is increased by sodium butyrate. Gut 1995, 36, 93-99.
20. Hatayama, H.; Iwashita, J.; Kuwajima, A.; Abe, T. The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. Biochem. Biophys. Res. Commun. 2007, 356, 599-603.
21. Deryugina, E. I.; Quigley, J. P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25, 9-34.
22. Williams, E. A.; Coxhead, J. M.; Mathers, J. C. Anticancer effects of butyrate: use of micro-array technology to investigate mechanisms. Proc. Nutr. Soc. 2003, 62, 107-115.
23. Basson, M. D.; Liu, Y.-W.; Hanly, A. M.; Emenaker, N. J.; Shenoy, S. G.; Gould Rothberg, B. E. Identification and comparative analysis of human colonocyte short-chain fatty acid response genes. J. Gastrointest. Surg. 2000, 4, 501-512.
24. Khan, A.; Greenman, J.; Archibald, S. J. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates. Curr. Med. Chem. 2007, 14, 2257-2277.
25. Crazzolara, R.; Johrer, K.; Johnstone, R. W.; Greil, R.; Kofler, R.; Meister, B.; Bernhard, D. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br. J. Heamatol. 2002, 119, 965-969.
26. Redondo-Munoz, J.; Escobar-Diaz, E.; Samaniego, R.; Terol, M. J.; Garcia-Marco, J. A.; Garcia-Pardo, A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by α4β1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006, 108, 3143-3151.
27. Ahmad, R.; Raina, D.; Trivedi, V.; Ren, J.; Rajabi, H.; Kharbanda, S.; Kufe, D. MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signalling. Nat. Cell Biol. 2007, 9, 1419-1427.
28. Thathiah, A.; Brayman, M.; Dharmaraj, N.; Julian, J. J.; Lagow, E. L.; Carson, D. D. Tumor necrosis factor alpha stimulates MUC1 synthesis and ectodomain release in a human uterine epithelial cell line. Endocrinology 2004, 145, 4192-4203.
29. Ten, R. M.; Paya, C. V.; Israel, N.; Le Bail, O.; Mattei, M. G.; Virelizier, J. L.; Kourilsky, P.; Israel, A. The characterization of the promoter of the gene encoding the p50 subunit of NF-κB indicates that it participates in its own regulation. EMBO J. 1992, 11, 195-203.
30. Monks, N. R.; Pardee, A. B. Targeting the NF-κB pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs. J. Cell. Biochem. 2006, 98, 221-233.
31. Liu, T.; Guo, Z.; Yang, Q.; Sad, S.; Jennings, H. J. Biochemical engineering of surface α2,8 polysialic acid for immunotargeting tumor cells. J. Biol. Chem. 2000, 275, 32832-32836.
32. Wang, Q.; Zhang, J.; Guo, Z. Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell. Bioorg. Med. Chem. 2007, 15, 7561-7567.
33. Meutermans, W.; Le, G. T.; Becker, B. Carbohydrates as scaffolds in drug discovery. ChemMedChem 2006, 1, 1164-1194.
34. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6, 38-51.
35. Miki, K.; Nagai, T.; Suzuki, K.; Tsujimura, R.; Koyama, K.; Kinoshita, K.; Furuhata, K.; Yamada, H.; Takahashi, K. Anti-influenza virus activity of biflavonoids. Bioorg. Med. Chem. Lett. 2007, 17, 772-775.
36. Albini, A.; Benelli, R.; Noonan, D. M.; Brigati, C. The "chemoinvasion assay": a tool to study tumor and endothelial cell invasion of basement membranes. Int. J. Dev. Biol. 2004, 48, 563-571.
37. Jourdian, G. W.; Dean, L.; Roseman, S. The sialic acids. XI. A periodate-resorcinol method for the quantitative estimation of free sialic acids and their glycosides. J. Biol. Chem. 1971, 246, 430-435.
38. Yarema, K. J.; Goon, S.; Bertozzi, C. R. Metabolic selection of glycosylation defects in human cells. Nat. Biotechnol. 2001, 19, 553-558.
39. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
40. ΔΔCT method. Methods 2001, 25, 402-408.
41. Wang, Z.; Sun, Z.; Li, A. V.; Yarema, K. J. Roles for GNE outside of sialic acid biosynthesis: modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation and apoptosis, and ERK1/2 phosphorylation. J. Biol. Chem. 2006, 281, 27016-27028.